MX2019003685A - Composicion farmaceutica para uso en el tratamiento terapeutico del cancer y complicaciones del cancer. - Google Patents

Composicion farmaceutica para uso en el tratamiento terapeutico del cancer y complicaciones del cancer.

Info

Publication number
MX2019003685A
MX2019003685A MX2019003685A MX2019003685A MX2019003685A MX 2019003685 A MX2019003685 A MX 2019003685A MX 2019003685 A MX2019003685 A MX 2019003685A MX 2019003685 A MX2019003685 A MX 2019003685A MX 2019003685 A MX2019003685 A MX 2019003685A
Authority
MX
Mexico
Prior art keywords
cancer
pharmaceutical composition
complications
therapeutic treatment
beta
Prior art date
Application number
MX2019003685A
Other languages
English (en)
Inventor
Faustin Monkam Nitcheu Guy
Original Assignee
Faustin Monkam Nitcheu Guy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1771115A external-priority patent/FR3058060B1/fr
Application filed by Faustin Monkam Nitcheu Guy filed Critical Faustin Monkam Nitcheu Guy
Publication of MX2019003685A publication Critical patent/MX2019003685A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se refiere a una composición farmacéutica, caracterizada porque comprende, como sustancia activa, una combinación de beta-elemeno, lupeol y un agente farmacéuticamente activo seleccionado entre cinamaldehído, 2-hidroxicinamaldehído, 2'-benzoiloxicinalmaldehído, betasitosterol, curcumina, y mezclas de los mismos.
MX2019003685A 2016-10-31 2017-10-25 Composicion farmaceutica para uso en el tratamiento terapeutico del cancer y complicaciones del cancer. MX2019003685A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR1670645A FR3058058A1 (fr) 2016-10-31 2016-10-31 Composition pharmaceutique comprenant en tant que principe actif une combinaison de beta-elemene, de lupeol et du 2-hydroxycinnamaldehyde et/ou du 2-benzoyloxycinnalmaldehyde et/ou beta-sitosterol
FR1670666A FR3058059B1 (fr) 2016-10-31 2016-11-08 Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
FR1771115A FR3058060B1 (fr) 2016-10-31 2017-10-23 Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
PCT/IB2017/056612 WO2018078539A1 (fr) 2016-10-31 2017-10-25 Composition pharmaceutique utilisée pour le traitement thérapeutique du cancer et ses complications

Publications (1)

Publication Number Publication Date
MX2019003685A true MX2019003685A (es) 2019-09-26

Family

ID=58401825

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003685A MX2019003685A (es) 2016-10-31 2017-10-25 Composicion farmaceutica para uso en el tratamiento terapeutico del cancer y complicaciones del cancer.

Country Status (10)

Country Link
EP (1) EP3429568A1 (es)
KR (1) KR20190077449A (es)
CN (1) CN109562080B (es)
CA (1) CA3043456A1 (es)
FR (2) FR3058058A1 (es)
IL (1) IL266623A (es)
MA (1) MA44413A (es)
MX (1) MX2019003685A (es)
WO (1) WO2018078539A1 (es)
ZA (1) ZA201902910B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109438166B (zh) * 2018-11-08 2021-06-04 石药集团远大(大连)制药有限公司 (1S,2S,4S)-β-榄香烯及其制备方法和应用
FR3100128B1 (fr) * 2019-08-30 2022-02-18 Nitcheu Guy Faustin Monkam Composition pharmaceutique destinée à inhiber l’infectiosité du VIH, à traiter le syndrome d’immunodéficience acquise (SIDA) et ses complications
US20230355544A1 (en) * 2019-12-03 2023-11-09 Sichuan Honghe Biotechnology Co., Ltd Pharmaceutical Composition Containing Elemene, Preparation Method Therefor, And Use Thereof
CN111909897B (zh) * 2020-08-14 2021-12-21 宜兴市人民医院 Ruvbl2在调控人脐带间质干细胞增殖和/或分化中的应用
CN113018312B (zh) * 2021-01-11 2022-12-09 南开大学 一种降低肿瘤辐射抗性的纳米放疗增敏剂及其制备方法和应用
US20220362227A1 (en) * 2021-05-11 2022-11-17 Roseman University Of Health Sciences Composition of phytonutrients for diabetes management
KR20230167257A (ko) 2022-05-31 2023-12-08 전남대학교산학협력단 1개 이상의 유효성분을 포함하는 신장섬유화증 예방, 개선 또는 치료용 조성물
CN117482049B (zh) * 2023-12-29 2024-03-26 中国人民解放军总医院海南医院 一种抗肿瘤组合物

Also Published As

Publication number Publication date
FR3058059B1 (fr) 2020-07-10
IL266623A (en) 2019-07-31
FR3058059A1 (fr) 2018-05-04
FR3058058A1 (fr) 2018-05-04
WO2018078539A1 (fr) 2018-05-03
KR20190077449A (ko) 2019-07-03
ZA201902910B (en) 2020-06-24
CN109562080A (zh) 2019-04-02
CN109562080B (zh) 2022-12-20
CA3043456A1 (en) 2018-05-03
MA44413A (fr) 2021-03-17
EP3429568A1 (fr) 2019-01-23

Similar Documents

Publication Publication Date Title
MX2019003685A (es) Composicion farmaceutica para uso en el tratamiento terapeutico del cancer y complicaciones del cancer.
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
WO2015095227A3 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
PH12018502738A1 (en) Compositions, devices, and methods for the treatment of alcohol use disorder
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
PH12016501527A1 (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2016014696A (es) Combinaciones de formoterol y budesonida para el tratamiento de enfermedad pulmonar obstructiva cronica.
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
AR101901A1 (es) Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod
EP3881843A4 (en) PROPHYLACTIC OR THERAPEUTIC AGENT AND MEDICAL COMPOSITION FOR IL-31 MEDIATED DISEASE
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
PH12018502139A1 (en) Phosphaplatin liquid formulations
EP3362096A4 (en) OPHTHALMIC TREATMENT COMPOSITION AND CARRIER FOR THE RELEASE OF PHARMACEUTICAL SUBSTANCES OR THERAPEUTICS
EP3804722A4 (en) TREATMENT AGENT AND PHARMACEUTICAL COMPOSITION AGAINST GLIOMA
AR109019A1 (es) Formas de dosis orales en bajas dosis para el tratamiento de enfermedades
WO2018094035A3 (en) Ligand ionophore conjugates
MX2018003564A (es) 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
EP3865141A4 (en) ANTI-CANCER AGENT, PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND KIT
GB201817346D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of diseases